Scroll for more

About

 

Peter Lichtlen, M.D., Ph.D.
Chief Medical Officer

 

Dr. Lichtlen became our Chief Medical Officer in July 2014, after joining Sucampo in 2011 as Senior Medical Officer and Vice President of European Operations. In addition to his direct role at the company, he was a consultant to Sucampo, providing support to the company in areas such as clinical development, reviews of protocols, the NICE endorsement for AMITIZA® in the U.K., European Medical Affairs activities, as well as medical support for the lubiprostone pediatric functional constipation program from September 2013 to July 2014.

Prior to joining Sucampo, Dr. Lichtlen held various roles of increasing responsibility at ESBATech AG (acquired by Alcon/Novartis in 2009), of Schlieren, Switzerland, which he joined in 2000. At ESBATech, Dr. Lichtlen served as Medical Director/Head Clinical Research and Development, and a member of its senior management team, from 2004 to 2010. In those roles, he was responsible for setting and managing clinical development strategy, serving as the scientific and medical lead for its clinical programs, overseeing interactions with regulatory agencies in Europe, and identifying new molecular targets and clinical indications, among other duties.

Dr. Lichtlen also co-founded Numab AG, a Swiss biotechnology company that innovates antibody-based therapeutics, where he remains a member of the Board of Directors.

Dr. Lichtlen currently serves on the scientific advisory board of Apidel SA, a drug delivery company. Dr. Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of four patents.

Dr. Lichtlen earned a bachelor’s degree in business administration, and doctorate degrees in medicine and molecular biology at the University of Zurich.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.